Citations

Showing 10 of 108104 citations.

New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma
Moore, Donald C. , Peery, Matthew R. , Tobon, Katherine, Raheem, Farah , Hwang, Grace, Alhennawi, Lin, Hughes, Mitchell E.

Mayo Clinic

Journal of Oncology Pharmacy Practice | April 26, 2022 | Volume: 28 | Issue: 8 | Pages: 1848-1858

10.1177/10781552221096165 | PMID 35469489 Get It

Diffuse large B-cell lymphoma (DLBCL) is the most common form of aggressive non-Hodgkin lymphoma. Approximately 40% of patients with DLBCL will experience disease relapse or will be refractory to first line chemoimmunotherapy, necessitating second-line salvage therapy. This has historically consisted of platinum-based chemotherapy regimens followed by autologous hematopoietic stem cell transplantation with curative intent for transplant-eligible patients or palliative chemotherapy for transplant-ineligible patients. In recent years there have been several new therapeutic agents approved for the treatment of relapsed/refractory DLBCL, thereby expanding the therapeutic landscape. These agents include polatuzumab vedotin, tafasitamab, loncastuximab tesirine, selinexor, and anti-CD19 chimeric antigen receptor T-cell therapies such as axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. This review summarizes the pharmacology, efficacy, safety, dosing, and administration of new agents recently approved for the treatment of relapsed/refractory DLBCL.
Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT
Kanack, Adam J. , Splinter, Noah P., Smock, Kristi J. , Moser, Karen , Padmanabhan, Anand , Abou-Ismail, Mouhamed Yazan , Smock, Kristi J , Moser, Karen A , Padmanabhan, Anand

Mayo Clinic

Blood Advances | April 25, 2022 | Volume: 6 | Issue: 18 | Pages: 5327-5329

10.1182/bloodadvances.2022007753 | PMID 35468623 Get It

Workflow to develop 3D designed personalized neonatal CPAP masks using iPhone structured light facial scanning
Kamath, A. , Kamath, Marielle J., Ekici, Selin , Stans, Anna Sofia, Colby, Christopher E. , Matsumoto, Jane M., Wylam, Mark E.

Mayo Clinic

No container title available | April 25, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1578678/v1 Get It

Abstract Background Continuous positive airway pressure (CPAP) is a common mode of respiratory support used in neonatal intensive care units. In preterm infants, nasal CPAP (nCPAP) therapy is often delivered via soft, biocompatible nasal mask suitable for long-term direct-skin contact and held firmly against face. Limited sizes of nCPAP mask contribute to mal-fitting related complications and adverse outcomes in this fragile population. We hypothesized that custom-fit nCPAP masks will improve the fit with less skin pressure and strap tension improving efficacy and reducing complications associated with nCPAP therapy in neonates. Methods After IRB approval and informed consent we evaluated several methods to develop 3D facial models to test custom 3D nCPAP masks. These methods included camera-based photogrammetry, laser scanning and structured light scanning using a Bellus3D Face Camera Pro and iPhone X running either Bellus3D FaceApp for iPhone, or Heges application. This data was used to provide accurate 3D neonatal facial models. Using CAD software nCPAP inserts were designed to be placed between proprietary nCPAP mask and the model infant’s face. The resulted 3D designed nCPAP mask was form fitted to the model face. Subsequently, nCPAP masks were connected to a ventilator to provide CPAP and calibrated pressure sensors and co-linear tension sensors were placed to measures skin pressure and nCPAP mask strap tension. Results Photogrammetry and laser scanning were not suited to the neonatal face. However, structured light scanning techniques produced accurate 3D neonatal facial models. Individualized nCPAP mask inserts manufactured using 3D printed molds and silicon injection were effective at decreasing surface pressure and mask strap pressure in some cases by more than 50% compared to CPAP masks without inserts. Conclusions We found that readily available structured light scanning devices such as the iPhoneX are a low cost, safe, rapid, and accurate tool to develop accurate models of preterm infant facial topography. Structured light scanning developed 3D nCPAP inserts applied to commercially available CPAP masks significantly reduced skin pressure and strap tension at clinically relevant CPAP pressures when utilized on model neonatal faces. This workflow maybe useful at producing individualized nCPAP masks for neonates reducing complications due to malfit.
An Algorithmic Approach to Managing Parotid Duct Injury Following Buccal Fat Pad Removal
Weissler, Jason M., Omar, Mohamed , Gryskiewicz, Joseph M. , Chopra, Karan , Mohamed, Omar, Mohamed, Omar, Gryskiewicz, Joe M.

Mayo Clinic

Aesthetic Surgery Journal Open Forum | April 25, 2022 | Volume: 4 | Issue: No issue available | Pages: No page available

10.1093/asjof/ojac032 | PMID 35662908 Get It

Abstract The principles of achieving an aesthetically pleasing and harmonious facial appearance are influenced by our evolving understanding of the three-dimensional topography of the face coupled with novel approaches to midface volumization and contouring. In parallel with the evolving landscape of facial aesthetic surgery, an increasing number of publications have emerged focusing on the role of intraoral buccal fat pad removal (BFPR) for the purposes of aesthetic midface contouring. The authors sought to emphasize an underreported and potentially preventable and untoward complication involving iatrogenic parotid duct injury following BFPR. The purpose of this publication is 3-fold: (1) to review the relevant anatomy and literature on intraoral BFPR, (2) to present a case example of this complication, and (3) to discuss treatment options as part of a proposed management algorithm. The authors detail the surgical indications for performing BFPR and review the relevant anatomic considerations. Complication prevention strategies are outlined, and details regarding avoidance of parotid duct injury are reviewed. The diagnostic criteria and clinical presentation of parotid duct injuries following BFPR are comprehensively outlined. The authors present a clinically actionable algorithm for managing a suspected or diagnosed parotid duct injury following BFPR. A clinical case example is discussed to highlight this complication, the diagnostic criteria, and the systematic and algorithmic approach to management. Intraoral BFPR is an incredibly valuable and powerful procedure that can improve facial contour in patients with buccal lipodystrophy or buccal fat pad pseudoherniation. The authors propose a proper diagnostic approach and treatment algorithm to manage this untoward complication. Level of Evidence: 5
Optimizing techniques for measuring anal resting and squeeze pressures with high‐resolution manometry
Oblizajek, Nicholas R. , Deb, Brototo , Ramu, Shivabalan Kathavarayan , Chunawala, Zainali , Feuerhak, Kelly, Bailey, Kent R. , Bharucha, Adil E. , Kathavarayan Ramu, Shivabalan Shiva, Oblizajek, Nicholas R

Mayo Clinic

Neurogastroenterology & Motility | April 25, 2022 | Volume: 34 | Issue: 10 | Pages: No page available

10.1111/nmo.14383 | PMID 35468247 Get It

AbstractBackgroundThe optimal methods for measuring and analyzing anal resting and squeeze pressure with high‐resolution manometry (HRM) are unclear.MethodsAnal resting and squeeze pressures were measured with HRM in 90 healthy women, 35 women with defecatory disorders (DD), and 85 with fecal incontinence (FI). Pressures were analyzed with Manoview™ software and a customized approach. Resting pressures measured for 20, 60, and 300 s were compared. During the squeeze period, (3 maneuvers, 20 s each), the squeeze increment, which was averaged over 5, 10, 15, and 20 s, and squeeze duration were evaluated.ResultsCompared to healthy women, the anal resting pressure, squeeze pressure increment, and squeeze duration were lower in FI (p ≤ 0.04) but not in DD. The 20, 60, and 300 s resting pressures were strongly correlated (concordance correlation coefficients = 0.96–0.99) in healthy and DD women. The 5 s squeeze increment was the greatest; 10, 15, and 20 s values were progressively lower (p < 0.001). The squeeze pressure increment and duration differed (p < 0.01) among the three maneuvers in healthy and DD women but not in FI women. The upper 95th percentile limit for squeeze duration was 19.5 s in controls, 19.9 s in DD, and 19.3 s in FI. Adjusted for age, resting pressure, and squeeze duration, a greater squeeze increment was associated with a lower risk of FI versus health (OR, 0.96; 95% CI, 0.94–0.97).ConclusionsThese findings suggest that anal resting and squeeze pressures can be accurately measured over 20 s. In most patients, one squeeze maneuver is probably sufficient.
Fasting pyloric diameter and distensibility by functional endoluminal imaging probe in unsedated healthy volunteers
Zheng, Ting , Vosoughi, Kia , Busciglio, Irene, Tebay, Lisa, Burton, Duane D. , Camilleri, Michael , Burton, Duane

Mayo Clinic

Neurogastroenterology & Motility | April 25, 2022 | Volume: 34 | Issue: 10 | Pages: No page available

10.1111/nmo.14386 | PMID 35468258 Get It

AbstractBackgroundRecent studies with functional endoluminal imaging probe (EndoFLIP®) measure physiologic characteristics of the pylorus. EndoFLIP® has the potential to select optimal candidates for gastric peroral endoscopic myotomy (G‐POEM). Normative values of the pylorus using EndoFLIP® have not been established.MethodsTwenty‐four healthy volunteers (20–56 years old; 15 females) underwent unsedated, transoral EndoFLIP® measurements of the pylorus after 8 h of fasting. Measurements of diameter (DM), balloon pressure, and distensibility index (DI) of the pylorus were obtained twice over 5 min at 40, 50, and 60 ml balloon distensions.Key ResultsPyloric DM at 40, 50, and 60 ml balloon distensions were 13.0 ± 2.5, 14.3 ± 1.8, and 17.2 ± 2.0 mm, respectively. DM with 60 ml distension was notably higher than with 40 and 50 ml distensions. Pyloric DI at 40, 50, and 60 ml distensions were 10.9 ± 4.8, 11.3 ± 5.8, and 11.1 ± 4.3 mm2/mm Hg, respectively (p = 0.86). Linear regression and Bland–Altman plots showed similar distribution of the DM and DI during the second minute compared with the full 5‐min measurements at 50 ml distension, as well as between two sequential measurements using 50 ml distension. With 50 ml balloon distension, intraindividual coefficients of variation (COVintra) for DM and DI were 13.8% and 29.6%, respectively, and interindividual COV (COVinter) were 12.6% and 51.3%, respectively. Similar reproducibility was obtained with 40 ml balloon distension.Conclusions and InferencesUnsedated EndoFLIP® can be used to characterize human fasting pyloric diameter and distensibility, with best performance observed with 40 ml and 50 ml distensions and data collection during the second minute. Normative values reported serve as reference values for future studies.
Letter by Natale et al Regarding Article, “Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial”
Natale, Andrea , Kar, Saibal , Holmes, David R. , Holmes, David R , Kar, Saibal , Natale, Andrea

Mayo Clinic

Circulation | April 25, 2022 | Volume: 145 | Issue: 17 | Pages: No page available

10.1161/circulationaha.121.057567 | PMID 35467955 Get It

Efficacy of Hepatitis B Vaccination with a Novel Immunostimulatory Sequence Adjuvant (Heplisav-B) in Patients With Inflammatory Bowel Disease
Kwon, Joshua , Hashash, Jana G. , Picco, Michael F., Kwon, Joshua Y , Hashash, Jana G , Daoud, Nader , Farraye, Francis A.

Mayo Clinic

Inflammatory Bowel Diseases | April 25, 2022 | Volume: 29 | Issue: 2 | Pages: 254-259

10.1093/ibd/izac079 | PMID 35468183 Get It

AbstractBackgroundOwing to the use of immunosuppressive agents, patients with inflammatory bowel disease (IBD) have an increased risk of vaccine preventable diseases, including infection with hepatitis B virus (HBV). Heplisav-B, an FDA-approved vaccine, is more effective (90% to 100%) than Engerix-B (70.5% to 90.2%) at inducing immunity to HBV in clinical studies. Available data on efficacy of Heplisav-B vaccine in patients with IBD are limited.MethodsThis retrospective observational study included patients age 18 years and older with ulcerative colitis (UC) or Crohn’s disease (CD) who received 1 or 2 doses of Heplisav-B vaccine and had postvaccination serologic testing. Prior to immunization, all participants were seronegative for HBsAb antibodies (HBsAb) measured as &lt;10 IU/mL. Postvaccination HBsAb of ≥10 IU/mL was considered successful vaccination. Patient demographics, disease characteristics, and medications were abstracted.ResultsOne hundred six patients were included in the analysis. Median age was 43 years, and 44 (42%) were female. Thirty-nine patients (37%) had UC, whereas 67 (63%) had CD. Eighty-three patients (78.3%) had active immunity after vaccination with Heplisav-B, with median postvaccination HBsAb levels of 114 IU/L. Patients with chronic obstructive pulmonary disease, chronic kidney disease, diabetes mellitus, immunomodulator use, or those on 2 or more of immunosuppressive medications were less likely to respond to Heplisav-B, though these findings were not statistically significant on a multivariate analysis aside from chronic kidney disease.ConclusionsHeplisav-B, a 2-dose vaccine, is an effective vaccine for HBV in patients with IBD. In our study, its overall efficacy (78.3%) is greater than that reported for the presently available 3-dose vaccination (Engerix) in patients with IBD.
Neurologic Manifestations of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Hospitalized Patients During the First Year of the COVID-19 Pandemic
Cervantes-Arslanian, Anna M., Venkata, Chakradhar, Anand, Pria, Burns, Joseph D., Ong, Charlene J., LeMahieu, Allison M., Schulte, Phillip J., Singh, Tarun D., Rabinstein, Alejandro A., Deo, Neha, Bansal, Vikas, Boman, Karen, Garces, Juan Pablo Domecq, Armaignac, Donna Lee, Christie, Amy B., Melamed, Roman R., Tarabichi, Yasir, Cheruku, Sreekanth R., Khanna, Ashish K., Denson, Joshua L., Banner-Goodspeed, Valerie M., Anderson, Harry L., Gajic, Ognjen, Kumar, Vishakha K., Walkey, Allan, Kashyap, Rahul, Group, on behalf of the Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator, Bansal, Vikas , Singh, Tarun D. , Kaur, Nirmaljot , Danesh, Valerie , Заболотских, И. Б. , Armaignac, Donna Lee , Nawathe, Pooja , Tarabichi, Yasir , Cavallazzi, Rodrigo , Anand, Pria , Domecq Garces, Juan Pablo, Bansal, Vikas , Kaur, Nirmaljot , Domecq Graces, Juan Pablo , Cervantes-Arslanian, Anna M., Venkata, Chakradhar, Anand, Pria, Burns, Joseph D., Ong, Charlene J., LeMahieu, Allison M., Schulte, Phillip J., Singh, Tarun D., Rabinstein, Alejandro A., Deo, Neha, Bansal, Vikas, Boman, Karen, Christie, Amy B., Melamed, Roman R., Cheruku, Sreekanth R., Khanna, Ashish K., Denson, Joshua L., Banner-Goodspeed, Valerie M., Anderson, Harry L., Gajic, Ognjen, Kumar, Vishakha K., Walkey, Allan, Kashyap, Rahul, Group, on behalf of the Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator

Mayo Clinic

Critical Care Explorations | April 25, 2022 | Volume: 4 | Issue: 4 | Pages: e0686

10.1097/cce.0000000000000686 | PMID 35492258 Get It

OBJECTIVES: To describe the prevalence, associated risk factors, and outcomes of serious neurologic manifestations (encephalopathy, stroke, seizure, and meningitis/encephalitis) among patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. DESIGN: Prospective observational study. SETTING: One hundred seventy-nine hospitals in 24 countries within the Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study COVID-19 Registry. PATIENTS: Hospitalized adults with laboratory-confirmed SARS-CoV-2 infection. INTERVENTIONS: None. RESULTS: Of 16,225 patients enrolled in the registry with hospital discharge status available, 2,092 (12.9%) developed serious neurologic manifestations including 1,656 (10.2%) with encephalopathy at admission, 331 (2.0%) with stroke, 243 (1.5%) with seizure, and 73 (0.5%) with meningitis/encephalitis at admission or during hospitalization. Patients with serious neurologic manifestations of COVID-19 were older with median (interquartile range) age 72 years (61.0–81.0 yr) versus 61 years (48.0–72.0 yr) and had higher prevalence of chronic medical conditions, including vascular risk factors. Adjusting for age, sex, and time since the onset of the pandemic, serious neurologic manifestations were associated with more severe disease (odds ratio [OR], 1.49; p < 0.001) as defined by the World Health Organization ordinal disease severity scale for COVID-19 infection. Patients with neurologic manifestations were more likely to be admitted to the ICU (OR, 1.45; p < 0.001) and require critical care interventions (extracorporeal membrane oxygenation: OR, 1.78; p = 0.009 and renal replacement therapy: OR, 1.99; p < 0.001). Hospital, ICU, and 28-day mortality for patients with neurologic manifestations was higher (OR, 1.51, 1.37, and 1.58; p < 0.001), and patients had fewer ICU-free, hospital-free, and ventilator-free days (estimated difference in days, –0.84, –1.34, and –0.84; p < 0.001). CONCLUSIONS: Encephalopathy at admission is common in hospitalized patients with SARS-CoV-2 infection and is associated with worse outcomes. While serious neurologic manifestations including stroke, seizure, and meningitis/encephalitis were less common, all were associated with increased ICU support utilization, more severe disease, and worse outcomes.
A signature based on costimulatory molecules for the assessment of prognosis and immune characteristics in stomach adenocarcinoma
Chen, Bangjie , Yao, Yong , Mao, Deshen, Li, Conghan, Wang, Xingyu , Sheng, Shuyan , Zhang, Lizhi , Wang, Xinyi , Deng, Jianyi , Bentley, Rachel , Shao, Wei , Li, Conghan, Chen, Sanwei , Xu, Wentao , Sun, Chenyu , Zhou, Qin Yuan , Lowe, Scott W. , Li, Haiwen

Mayo Clinic

No container title available | April 25, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1577855/v1 Get It

Abstract Although costimulatory molecules have been shown to boost antitumor immune responses, their significance in stomach adenocarcinoma (STAD) is unknown. The purpose of this study was to examine the gene expression patterns of costimulatory molecule genes in STAD and to develop a predictive signature to aid in therapy selection and outcome prediction. We used 60 costimulatory family genes from prior research to conduct the first complete costimulatory molecule analysis in STAD patients. For the two groups discovered, consensus clustering analysis based on these 60 genes indicated unique distribution patterns and prognostic differences. Then, using Lasso and Cox regression analysis, 9 costimulatory molecular gene pairs (CMGPs) of prognostic value were discovered. With these 9 CMGPs, we were able to develop a costimulatory molecule-related prognostic signature, which performed well in an external dataset. For STAD patients, the signature was proved to be a risk factor independent of clinical characteristics, indicating that this may be employed in conjunction with clinical considerations. An further connection between the signature and immunotherapy response was discovered. People who had high mutation rates, an abundance of infiltrating immune cells, and an immunosuppressive milieu were classed as high-risk. It is possible that patients classed as high-risk have a better prognosis for immunotherapy since these patients have greater cytolytic activity scores and immunophenoscores of CTLA4 and PD-L1/PD-L2 blocker As a consequence, clinicians might use our signature to better assess patient prognosis and develop treatment plans.